-+ 0.00%
-+ 0.00%
-+ 0.00%

Imunon reports Phase 2 OVATION 2 data; median overall survival rises by 14.7 months with IMNN-001 in newly diagnosed advanced ovarian cancer

Reuters·03/25/2026 12:05:56

Please log in to view news